Article Information
PubMed
History
- Published online October 24, 2021.
Copyright & Usage
© 2021 CMA Joule Inc. or its licensors This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/
Author Information
- Danica Quickfall, MD CM,
- Nick Daneman, MD,
- Adam A. Dmytriw, MD MPH,
- David N. Juurlink, MD PhD
- Department of Medicine (Quickfall, Daneman, Juurlink), Sunnybrook Health Sciences Centre; Departments of Medicine and Paediatrics (Quickfall, Daneman, Juurlink), University of Toronto; Institute for Clinical Evaluative Sciences (ICES) (Daneman, Juurlink), Toronto, Ont.; Neuroendovascular Program (Dmytriw), Massachusetts General Hospital, Harvard Medical School, Boston, Mass.; Ontario Poison Centre (Juurlink), Toronto, Ont.
- Correspondence to: David Juurlink, david.juurlink{at}ices.on.ca
Statistics from Altmetric.com
In this issue
Article tools
Respond to this article
Jump to section
- Article
- Metronidazole-induced neurotoxicity is underappreciated
- Metronidazole-induced neurotoxicity can present with a variety of clinical syndromes
- Dose and duration of treatment are the primary risk factors, but symptoms may appear early and with small doses
- Up to 90% of patients with central nervous system involvement have characteristic lesions on magnetic resonance imaging (MRI)
- Discontinuing metronidazole usually results in improvement
- Footnotes
- References
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.
More in this TOC Section
Similar Articles
Collections
